Systematic reviews and meta-analyses. PBRC will conduct rigorous reviews of the evidence in support of biomarkers and meta-analytic estimates of the validity, efficacy, and utility of biomarker testing. PBRC will also track how these estimates vary from one clinical application of a particular biomarker to the next.
AERO graphing. AERO graphing is a qualitative method for representing entire research portfolios. This method, which was developed by Dr. Hey of PORTAL, depicts studies as individual nodes on a graph, arranged by time of publication (or study completion) along the x-axis, and stratified by study parameters along the y-axis. To learn more about AERO Graphs, click here.
There will be four major projects in the initial phase of this program.
4.1 Cardiovascular Disease
Study of biomarkers that modulate HDL, LDL, and triglycerides and their interactions with all drug classes intended to affect them.
Study of EGFR testing to explore biomarker development in oncology and a new modality for evaluating the efficiency of precision medicine research.
4.3 Alzheimer's Disease
Study of amyloid-centric pharmaceuticals for Alzheimer’s disease to evaluate the amyloid-beta hypothesis and its correlation with disease progression.
Study of predictive biomarkers in tuberculosis, particularly the 2-month sputum culture conversion as a surrogate for stable cure of tuberculosis.